Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Leukemia. 2010 Sep 30;24(11):1893–1900. doi: 10.1038/leu.2010.191

Figure 1.

Figure 1

Complete blood counts with manual differential were performed before and after administration of autologous ISF35-transduced cells (a). ALC was normalized to the count obtained pre-treatment on the day of infusion (day 0) and plotted for each subject by dose level. The sum product of bidimensional lymph node measurements by palpation in three nodal regions was used as the measure of lymph node bulk (b). Measures were taken pre- (day 0) and post-infusion of autologous ISF35-transduced CLL cells. These data points were normalized to day 0 and presented for each patient by dose level. Consistent reductions in normalized ALC and lymph node bulk were noted acutely following treatment.